research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
== History == The FDA's approval of sildenafil in 1998 was a ground-breaking commercial event for the treatment of ED, with sales exceeding US$1 billion. Subsequently, the FDA approved both vardenafil and tadalafil in 2003. It initially was developed by the biotechnology company ICOS, and then again developed and marketed worldwide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. Tadalafil was approved in 2009 in the United States for the treatment of pulmonary arterial hypertension and is under regulatory review in other regions for this condition. In late November 2008, Eli Lilly sold the exclusive rights to commercialize tadalafil for pulmonary arterial hypertension in the United States to United Therapeutics for an upfront payment of $150 million. Tadalafil was discovered by Glaxo Wellcome (now GlaxoSmithKline) under a partnership between Glaxo and ICOS to develop new drugs that began in August 1991. In 1993, the Bothell, Washington, biotechnology company ICOS Corporation began studying compound IC351, a phosphodiesterase type 5 (PDE5) enzyme inhibitor. In 1994, Pfizer scientists discovered that sildenafil, which also inhibits the PDE5 enzyme, caused penile erection in males participating in a clinical study of a heart medicine. Although ICOS scientists were not testing compound IC351 for treating ED, they recognized its potential usefulness for treating that disorder. Soon, in 1994, ICOS received a patent for compound IC351 (structurally unlike sildenafil and vardenafil), and Phase 1 clinical trials began in 1995.
== History == There are two main theories as to the birthplace of grilled cold noodles. Some people believe that the dish originated in Mishan, while others believe that it started in Mudanjiang. According to legend, a man called Gai Guofeng (盖国峰) who sold snacks at the backdoor of Second Middle School of Mishan City liked to grill cold noodles for himself as a dish to go with wine. Unexpectedly, students of the Second Middle School of Mishan City found that the dish was very delicious, and it became very popular in Mishan.
Keratoconus is an eye disorder in which the cornea, the transparent front part of the eye, gradually thins and bulges outward into a cone shape. This causes distorted vision, including blurry vision, double vision, increased nearsightedness, irregular astigmatism, and light sensitivity, which can reduce quality of life. Both eyes are usually affected. The cause is not fully understood but likely involves a combination of genetic, environmental, and hormonal factors. Having a parent, sibling, or child with keratoconus increases risk significantly. Environmental risk factors include frequent eye rubbing and allergies. Diagnosis is typically made with corneal topography, which maps the shape of the cornea and reveals characteristic changes. In early stages, vision is often corrected with glasses or soft contact lenses. As the condition progresses, rigid or scleral contact lenses may be needed. In 2016, the FDA approved corneal collagen cross-linking to halt progression. If vision cannot be improved with contact lenses and the cornea becomes too thin or scarred, a corneal transplant may be necessary. Keratoconus affects about 1 in 2,000 people, though some estimates suggest it may be as common as 1 in 400. It typically develops in late childhood or early adulthood and occurs in all populations, though it may be more common in some ethnic groups, such as people of Asian descent. The name comes from the Greek kéras (cornea) and Latin cōnus (cone).
{\displaystyle {\begin{array}{lll}M({\ce {NaCl}})&=[22.98976928(2)+35.453(2)]\times M_{\text{u}}\\&=58.443(2){\text{ g/mol}}\\M({\ce {C12H22O11}})&=[12\times 12.0107(8)+22\times 1.00794(7)+11\times 15.9994(3)]\times M_{\text{u}}\\&=342.297(14){\text{ g/mol}}\end{array}}}
Sources: en.wikipedia.org
== Use as a biomarker == Dinosterol is used as a biomarker for organic matter derived from dinoflagellates in sediments and seawater. Biomarkers are organic compounds that are indicative of former life in sediments, seawater and oil. The presence of the saturated hydrocarbon counterpart, dinosterane, is used as evidence that some of the organic matter present in ancient sediments may have been derived from dinoflagellates.
, respectively. Their ratio is not equal to the equilibrium constant, which implies that thermodynamics does not constrain the ratio of the maximal rates. This explains that enzymes can be much "better catalysts" (in terms of maximal rates) in one particular direction of the reaction. One can also derive the two Michaelis constants
== Reception and legacy == Wolverine is one of the most popular Marvel superheroes. In 1995, he tied with Spider-Man as Marvel's most licensed character. In 2008, Wizard magazine ranked Wolverine 1st in their "200 Greatest Comic Book Characters of All Time" list. The same year, Empire ranked Wolverine 4th in their "50 Greatest Comic Book Characters" list. In 2014, Entertainment Weekly ranked Wolverine 1st in their "Let's rank every X-Man ever" list. Wolverine is typical of the tough antiheroes that emerged in American popular culture after the Vietnam War; his willingness to use deadly force and his brooding loner nature became standard characteristics for comic book antiheroes by the end of the 1980s. Wolverine was considered groundbreaking among comic book superheroes in demonstrating the traits of an antihero, which according to psychologist Suzana E. Flores includes being "psychologically damaged" as well as being "simultaneously depicted as superior due to [their] superhuman abilities and inferior due to [their] impetuousness, irrationality, or lack of thoughtful evaluation." Following Wolverine's creation, antiheroes became increasingly popular in comic books—especially in the 1990s—with the development of ones like the Punisher, Marv, Spawn, and Deadpool. The illustration of Wolverine's various mental health challenges, particularly recovery from major trauma or psychological trauma, have been identified by Flores as one of the reasons for his popularity.
Sources: en.wikipedia.org
=== Alternative splicing === There appear to be four isoforms due to splicing. Two of those are truncated on the 3' end of the protein from 266aa and 396aa. Additional location of alternative splice sites are from 79aa to 102aa and 246aa to 260aa.
== Development == Nerve growth normally ends in adolescence but can be re-stimulated with a molecular mechanism known as "notch signaling". If the axons of a neuron are damaged, as long as the cell body of the neuron is not damaged, the axons can regenerate and remake the synaptic connections with neurons with the help of guidepost cells. This is also referred to as neuroregeneration. The nerve begins the process by destroying the nerve distal to the site of injury allowing Schwann cells, basal lamina, and the neurilemma near the injury to begin producing a regeneration tube. Nerve growth factors are produced causing many nerve sprouts to bud. When one of the growth processes finds the regeneration tube, it begins to grow rapidly towards its original destination guided the entire time by the regeneration tube. Nerve regeneration is very slow and can take up to several months to complete. While this process does repair some nerves, there will still be some functional deficit as the repairs are not perfect.
Massively parallel reporter assays (MPRAs) and machine learning are newer ways to study gene regulation with reporter genes. One major use is in synthetic biology and gene therapy, where researchers can design better regulatory elements to control gene expression. For example, deep learning models trained on MPRA data have been used to optimize 5' untranslated regions (UTRs) for mRNA translation, enabling tailored designs that enhance gene-editing efficiency in the therapeutic context. This could make mRNA-based treatments more effective, as MPRAs also help identify how genetic variants affect gene expression, which is used in precision medicine and developing personalized treatments. Machine learning models trained on MPRA data can predict how different sequences impact gene activity, making it easier to design reporter genes that respond in specific ways. Combining MPRAs with next-gen sequencing also makes reporter gene experiments faster and more scalable. These advances could even improve mRNA-based vaccines and therapeutics by optimizing untranslated regions (UTRs) to boost stability and translation. For instance, modular MPRAs have uncovered context-specific regulatory sequences linked to type 2 diabetes, revealing enhancer-promoter interactions dependent on cell-specific transcription factors like HNF1. Similarly, MPRA screens of cardiac enhancer variants have pinpointed functional noncoding sequences influencing QT interval variability, directly linking genetic variation to disease-associated gene dysregulation.
Killed Arpad Horvath (75) at Meadow Park facility in London, Ontario Injected Sandra Towler (77) "with intent to murder" at a retirement home in Paris, Ontario Injected Beverly Bertram (68) "with intent to murder" at a private residence in Ingersoll, Ontario
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.